熱門資訊> 正文
Enliven Therapeutics GAAP每股收益为-0.54美元,击败0.02美元
2024-05-15 18:24
- Enliven Therapeutics press release (NASDAQ:ELVN): Q1 GAAP EPS of -$0.54 beats by $0.02.
- Balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026
More on Enliven Therapeutics
- Enliven Therapeutics announces $90M private placement to fund R&D activities
- Seeking Alpha’s Quant Rating on Enliven Therapeutics
- Historical earnings data for Enliven Therapeutics
- Financial information for Enliven Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。